![](/wp-content/uploads/2024/07/Screenshot-2024-07-17-at-2.17.06%E2%80%AFPM.png)
$599
Roche Positive Ph1 Oral GLP-1RA Obesity Results
Roche announced positive topline results for CT-996 (QD oral GLP-1RA) from its ongoing Ph1 trial in participants with and without T2DM (view CT.gov record). According to the press release, treatment with CT-996 resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks (p <0.001). Following the news, Roche’s stock increased ~7.5%. Below, FENIX provides highlights and brief thoughts on the potential CT-996 differentiation.